Last updated: March 13, 2026
What is NDC 70000-0012?
NDC 70000-0012 corresponds to Rucaparib, marketed as Rubraca, a PARP inhibitor used primarily for ovarian, prostate, and other cancers. It was approved by the FDA in December 2016 for ovarian cancer treatment.
Market Overview
Current Market Position
- indications: Ovarian cancer, prostate cancer, and other BRCA-mutated tumors.
- Approval dates:
- December 2016 (ovarian cancer)
- March 2020 (prostate cancer)
- Market reach: Focused on oncology segments with increasing adoption due to expanding indications and genetic testing.
Competition Landscape
| Drug Name |
Approved Indications |
Launch Year |
Manufacturer |
Market Share (2022) |
Price (per mg) |
Annual Revenue (2022) |
| Rucaparib (Rubraca) |
Ovarian, prostate |
2016, 2020 |
Clovis Oncology |
~25% |
$5.50 |
$350 million |
| Olaparib (Lynparza) |
Ovarian, breast, pancreatic, prostate |
2014 |
AstraZeneca / Merck |
~45% |
$7.00 |
$3 billion |
| Niraparib (Zejula) |
Ovarian, fallopian tube |
2017 |
Tesaro (GSK) |
~20% |
$6.00 |
$250 million |
| Talazoparib (Talzenna) |
Breast, ovarian |
2018 |
Pfizer |
~10% |
$9.00 |
$100 million |
Market Drivers
- Increasing use of PARP inhibitors due to expanding indications and improvements in genetic testing.
- Genetic testing adoption: More patients are tested for BRCA mutations, increasing qualifying patient population.
- Pricing and reimbursement trends: Payor coverage is narrowing price flexibility, especially with competitive pressure.
Market Size and Growth Projection
Global Oncology Market (2022 figures)
- Estimated at $230 billion, with PARP inhibitors constituting a growing segment.
- PARP inhibitor sales reached $5 billion globally in 2022 with a compound annual growth rate (CAGR) of approximately 20%.
Rucaparib-Specific Market Data
- U.S. sales: Approximately $350 million in 2022.
- Projected CAGR (2023-2028): 15-20%, driven by indication expansions and increased testing.
Forecast Breakdown (2023-2028)
| Year |
Estimated Market Size (USD) |
Rucaparib Revenue Estimate (USD) |
Key Factors |
| 2023 |
$280 billion |
$500 million |
Growing combination therapies |
| 2024 |
$300 billion |
$600 million |
Expanded indications, increased testing |
| 2025 |
$330 billion |
$800 million |
New approvals, improved diagnostics |
| 2026 |
$350 billion |
$1 billion |
Greater label expansion, market penetration |
| 2028 |
$370 billion |
$1.2 billion |
Competitive positioning solidifies |
Price Projections
Current Pricing
- Price per capsule: Approximately $11.00 to $13.00 based on dosing and discounts.
- Cost per mg: Approximate $5.50.
Factors Influencing Price Trends
- Market competition: Olaparib and Niraparib maintain higher prices; Rucaparib may face downward pressure.
- Reimbursement policies: U.S. and international payers are increasingly negotiating prices.
- Indication expansion: Growing label indications typically sustain or increase prices.
- Manufacturing costs: Marginal impact, as production efficiencies improve.
Price Trajectory (Next 5 Years)
| Year |
Estimated Price per mg |
Commentary |
| 2023 |
$5.50 - $6.00 |
Steady, competitive pricing |
| 2024 |
$5.50 |
Slight pressure from competitors |
| 2025 |
$5.75 |
Niche premium for expanded uses |
| 2026 |
$6.00 |
Slight upward drift with demand growth |
| 2028 |
$6.50 |
Possible premium for combination therapies |
Key Takeaways
- Rucaparib (NDC 70000-0012) operates in a competitive PARP inhibitor market with increasing indications.
- Market size in oncology is expected to continue growing at 15-20% CAGR through 2028.
- Revenue projections for Rucaparib estimate reaching approximately $1.2 billion globally by 2028.
- Price per mg is expected to remain stable in the short-term, with slight increases driven by increased indications and combination therapy opportunities.
- Competitive pressures from Olaparib and Niraparib influence pricing strategies, but expanded labeling and diagnostics could mitigate price erosion.
FAQs
1. What are the primary indications for Rucaparib?
Ovarian cancer (maintenance and treatment), prostate cancer, and other BRCA-mutated solid tumors.
2. How does Rucaparib compare in market share with other PARP inhibitors?
It holds approximately 25%, trailing Olaparib (~45%) and Niraparib (~20%), with room for expansion as indications grow.
3. What is the projected growth rate for Rucaparib revenues?
Between 15% and 20% CAGR through 2028.
4. How are pricing strategies affecting Rucaparib’s market position?
Stable pricing in the near term, with slight increases anticipated for expanded uses; price competition remains a concern.
5. What factors could disrupt market predictions?
Regulatory changes, patent expirations, new entrants, or shifts in payer policies could significantly alter projections.
References
- IQVIA. (2022). Oncology drug sales data.
- FDA. (2016). Approval notices for Rucaparib.
- Clovis Oncology. (2023). Annual reports.
- Evaluate Pharma. (2022). Oncology market forecasts.
- MarketWatch. (2023). PARP inhibitor market analysis.
